BlueCross BlueShield of Tennessee Medical Policy Manual

Trastuzumab Products (Herceptin®, Ontruzant®, Herzuma®, Ogivri®, Trazimera™, Kanjinti™)

Some agents on this policy may require step therapy See “Step Therapy Requirements for Provider Administered Specialty Medications” Document at: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

          I.    INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A.    FDA-Approved Indications

1.     Adjuvant breast cancer

Adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing node positive or node negative (estrogen receptor (ER)/progesterone receptor (PR) negative or with one high risk feature) breast cancer:

a.     As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel

b.     As part of a treatment regimen with docetaxel and carboplatin

c.     As a single agent following multi-modality anthracycline based therapy

2.     Metastatic breast cancer

a.     In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer

b.     As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

3.     Metastatic gastric cancer

In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease

B.    Compendial Uses

1.     HER2-positive breast cancer

a.     Neoadjuvant therapy

b.     Treatment of recurrent, advanced, unresectable, or stage IV (M1) disease

c.     Treatment for no response to preoperative systemic therapy

2.     Intra-cerebrospinal fluid (CSF) treatment for leptomeningeal metastases from HER2-positive breast cancer

3.     HER2-positive esophageal and esophagogastric junction cancer

4.     HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma

5.     HER2-amplified/positive and RAS and BRAF wild-type colorectal cancer

6.     HER2-positive salivary gland tumor

7.     HER2-positive hepatobiliary cancers

All other indications are considered experimental/investigational and not medically necessary.

         II.    DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: human epidermal growth factor receptor 2 (HER2) status (where applicable), RAS mutation status (where applicable), BRAF mutation status (where applicable)

       III.    CRITERIA FOR INITIAL APPROVAL

A.    Breast Cancer

1.     Authorization of up to 12 months may be granted for neoadjuvant treatment of HER2-positive breast cancer as part of a complete treatment regimen.

2.     Authorization of up to 12 months may be granted for adjuvant treatment of HER2-positive breast cancer.

3.     Authorization of 12 months may be granted for treatment of HER2-positive breast cancer with no response to preoperative systemic therapy, recurrent, advanced, unresectable, or metastatic (including brain metastases) disease.

4.     Authorization of 12 months may be granted for intra-CSF treatment for leptomeningeal metastases from HER2-positive breast cancer.

B.    Esophageal, Gastric, or Gastroesophageal Junction Cancer

Authorization of 12 months may be granted for treatment or palliative therapy of HER2-positive esophageal, gastric, or gastroesophageal junction cancer in combination with chemotherapy.

C.    Uterine Serous Carcinoma

Authorization of 12 months may be granted for treatment of HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma in combination with carboplatin and paclitaxel.

D.    Colorectal Cancer

Authorization of 12 months may be granted for treatment of unresectable, advanced, or metastatic colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma, when all of the following criteria are met:

1.     Member has HER2-positive/amplified disease

2.     The disease is negative (wild-type) for RAS (KRAS and NRAS) and BRAF mutations

3.     The requested medication will be used in combination with tucatinib, pertuzumab, or lapatinib

4.     Member has received prior therapy for the disease or is not appropriate for intensive therapy

E.    Salivary Gland Tumor

Authorization of 12 months may be granted for treatment of HER2-positive salivary gland tumors.

F.    Hepatobiliary Cancers

Authorization of 12 months may be granted for subsequent treatment of unresectable or metastatic HER2-positive hepatobiliary cancers (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer) when used in combination with pertuzumab

.

       IV.    CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.  Adjuvant and neoadjuvant treatment of breast cancer will be approved for a total of 12 months of therapy.

MEDICATION QUANTITY LIMITS

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION  

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1.     Herceptin [package insert]. South San Francisco, CA: Genentech, Inc.; February 2021.

2.     Kanjinti [package insert]. Thousand Oaks, CA: Amgen, Inc.; October 2022.

3.     Ogivri [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; February 2021.

4.     Trazimera [package insert]. Cork, Ireland: Pfizer Ireland Pharmaceuticals; November 2020.

5.     Herzuma [package insert]. Incheon, Republic of Korea: Celltrion, Inc.; May 2019.

6.     Ontruzant [package insert]. Incheon, Republic of Korea: Samsung Bioepis Co.; June 2021.

7.     The NCCN Drugs & Biologics Compendium® © 2023 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed January 27, 2023.

8.     National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 7, 2022.

9.     Thorpe LM, Schrock AB, Erlich RL, et al. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Head Neck. 2017;39(3): E40-E44.

10.  Clinical Pharmacology [database online]. Tampa, FL: Elsevier; https://www.clinicalkey.com/pharmacology [available with subscription]. Accessed December 7, 2022.

11.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Anal Carcinoma. Version 1.2023. Accessed January 27, 2023. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf

12.  Tukysa [package insert]. Bothell, WA: Seagen, Inc.; January 2023.

ORIGINAL EFFECTIVE DATE: 12/1/2016

MOST RECENT REVIEW DATE: 4/1/2024

ID_CHS

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.